Drug
Information |
Name | BP-897 |
Synonyms | BP-897 |
Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format |
Target | Alpha-1a adrenergic receptor |  | Inhibitor | [1] |
Alpha-1a adrenergic receptor |  | Inhibitor | [1] |
Alpha-2a adrenergic receptor |  | Inhibitor | [1] |
Dopamine D1 receptor |  | Inhibitor | [2] |
Dopamine D2 receptor |  | Inhibitor | [2] |
Dopamine D3 receptor |  | Inhibitor | [3] |
Dopamine D4 receptor |  | Inhibitor | [4] |
Serotonin 1a (5-HT1a) receptor |  | Inhibitor | [1] |
Serotonin 2b (5-HT2b) receptor |  | Inhibitor | [5] |
Ref 1 | J Med Chem. 2003 Aug 28;46(18):3822-39.Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. To Reference |
Ref 2 | Bioorg Med Chem Lett. 2004 Dec 6;14(23):5813-6.Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands. To Reference |
Ref 3 | Bioorg Med Chem Lett. 2010 Sep 1;20(17):5199-202. Epub 2010 Jul 6.Synthesis and in vitro binding studies of piperazine-alkyl-naphthamides: impact of homology and sulphonamide/carboxamide bioisosteric replacement on the affinity for 5-HT1A, alpha2A, D4.2, D3 and D2L receptors. To Reference |
Ref 4 | J Med Chem. 2005 May 5;48(9):3171-81.Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands. To Reference |
Ref 5 | J Med Chem. 2010 Nov 11;53(21):7573-86.Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs. To Reference |